Intrinsic caspase-8 activation mediates sensitization of erlotinib-resistant tumor cells to erlotinib/cell-cycle inhibitors combination treatment

Cell Death and Disease

Volumn 3, Issue 10, 2012, Pages

  Orzaez M ^a   Guevara, T ^a,b   Sancho, M ^a   Perez Paya E ^a,b  

^a CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

^b INSTITUTO DE BIOMEDICINA DE VALENCIA   (Spain)

Author keywords

Cancer; Cyclin dependent kinases; EGFR; Erlotinib; NBI1; Ripoptosome

Indexed keywords

CASPASE 10; CASPASE 8; CYCLIN A; CYCLIN DEPENDENT KINASE 2 INHIBITOR; ERLOTINIB; NBI 1; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG SENSITIZATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASE 8; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN A; CYCLIN-DEPENDENT KINASE 2; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; HUMANS; NEOPLASMS; QUINAZOLINES;

EID: 84870507634     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.155     Document Type: Article

References (48)

1. Foley J, Nickerson NK, Nam S, Allen KT, Gilmore JL, Nephew KP et al. EGFR signaling in breast cancer: bad to the bone. Semin Cell Dev Biol 2010; 21: 951-960.
2. Klijn JG, Berns EM, Foekens JA. Prognostic factors and response to therapy in breast cancer. Cancer Surv 1993; 18: 165-198.
3. LeMaistre CF, Meneghetti C, Howes L, Osborne CK. Targeting the EGF receptor in breast cancer treatment. Breast Cancer Res Treat 1994; 32: 97-103.
4. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19: 6550-6565.
5. Richard J, Sainsbury C, Farndon JR, Needham GK, Malcolm AJ, Harris AL. Epidermalgrowth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1987; 329: 1398-1402.
6. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37(Suppl 4): S3-S8.
7. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37(Suppl 4): S9-S15.
8. Ettinger DS. Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer. Oncologist 2006; 11: 358-373.
9. Doebele RC, Oton AB, Peled N, Camidge DR, Bunn Jr PA. New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. Lung Cancer 2010; 69: 1-12.
10. Gridelli C, Bareschino MA, Schettino C, Rossi A, Maione P, Ciardiello F. Erlotinib in nonsmall cell lung cancer treatment: current status and future development. Oncologist 2007; 12: 840-849.
11. Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over singleagent receptor targeting. Clin Cancer Res 2004; 10: 6487-6501.
12. Steins M, Thomas M, Geissler M. Erlotinib. Recent Results Cancer Res 2010; 184: 21-31.
13. Dickler MN, Cobleigh MA, Miller KD, Klein PM, Winer EP. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2009; 115: 115-121.
14. Cohen PR, Escudier SM, Kurzrock R. Cetuximab-associated elongation of the eyelashes: case report and review of eyelash trichomegaly secondary to epidermal growth factor receptor inhibitors. Am J Clin Dermatol 2011; 12: 63-67.
15. Ling YH, Li T, Yuan Z, Haigentz Jr M, Weber TK, Perez-Soler R. Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines. Mol Pharmacol 2007; 72: 248-258.
16. Yu Z, Boggon TJ, Kobayashi S, Jin C, Ma PC, Dowlati A et al. Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies. Cancer Res 2007; 67: 10417-10427.
17. Rexer BN, Arteaga CL. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog 2012; 17: 1-16.
18. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2011; 9: 16-32.
19. Martinelli E, Troiani T, Morgillo F, Rodolico G, Vitagliano D, Morelli MP et al. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells. Clin Cancer Res 2010; 16: 4990-5001.
20. O'Donovan N, Byrne AT, O'Connor AE, McGee S, Gallagher WM, Crown J. Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells. Invest New Drugs 2011; 29: 752-759.
21. Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci 2005; 30: 630-641.
22. Canela N, Orzaez M, Fucho R, Mateo F, Gutierrez R, Pineda-Lucena A et al. Identification of an hexapeptide that binds to a surface pocket in cyclin A and inhibits the catalytic activity of the complex cyclin-dependent kinase 2-cyclin A. J Biol Chem 2006; 281: 35942-35953.
23. Yamasaki F, Zhang D, Bartholomeusz C, Sudo T, Hortobagyi GN, Kurisu K et al. Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity. Mol Cancer Ther 2007; 6: 2168-2177.
24. Arteaga CL. Cdk inhibitor p27Kip1 and hormone dependence in breast cancer. Clin Cancer Res 2004; 10: 368S-371S.
25. Wu FY, Wang SE, Sanders ME, Shin I, Rojo F, Baselga J et al. Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity. Cancer Res 2006; 66: 2162-2172.
26. Fleming IN, Hogben M, Frame S, McClue SJ, Green SR. Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents. Clin Cancer Res 2008; 14: 4326-4335.
27. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19: 3267-3279.
28. van Engeland M, Nieland LJ, Ramaekers FC, Schutte B, Reutelingsperger CP. Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 1998; 31: 1-9.
29. Janicke RU. MCF-7 breast carcinoma cells do not express caspase-3. Breast Cancer Res Treat 2009; 117: 219-221.
30. Petrini JH, Stracker TH. The cellular response to DNA double-strand breaks: defining the sensors and mediators. Trends Cell Biol 2003; 13: 458-462.
31. Muller-Tidow C, Ji P, Diederichs S, Potratz J, Baumer N, Kohler G et al. The cyclin A1-CDK2 complex regulates DNA double-strand break repair. Mol Cell Biol 2004; 24: 8917-8928.
32. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998; 273: 5858-5868.
33. Yuan J, Adamski R, Chen J. Focus on histone variant H2AX: to be or not to be. FEBS Lett 2010; 584: 3717-3724.
34. Capasso H, Palermo C, Wan S, Rao H, John UP, O'Connell MJ et al. Phosphorylation activates Chk1 and is required for checkpoint-mediated cell cycle arrest. J Cell Sci 2002; 115(Pt 23): 4555-4564.
35. Danial NN. BCL-2 family proteins: critical checkpoints of apoptotic cell death. Clin Cancer Res 2007; 13: 7254-7263.
36. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004; 116: 205-219.
37. Lindsay J, Esposti MD, Gilmore AP. Bcl-2 proteins and mitochondria - specificity in membrane targeting for death. Biochim Biophys Acta 2011; 1813: 532-539.
38. Gyrd-Hansen M, Meier P. IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer 2010; 10: 561-574.
39. Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 2007; 12: 445-456.
40. Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell 2008; 133: 693-703.
41. Feoktistova M, Geserick P, Kellert B, Dimitrova DP, Langlais C, Hupe M et al. cIAPs block ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol Cell 2011; 43: 449-463.
42. Tenev T, Bianchi K, Darding M, Broemer M, Langlais C, Wallberg F et al. The ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell 2011; 43: 432-448.
43. Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 2007; 4: 1669-1679.
44. Janssens S, Tinel A. The PIDDosome, DNA-damage-induced apoptosis and beyond. Cell Death Differ 2012; 19: 13-20.
45. Bach S, Knockaert M, Reinhardt J, Lozach O, Schmitt S, Baratte B et al. Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem 2005; 280: 31208-31219.
46. Hitomi J, Christofferson DE, Ng A, Yao J, Degterev A, Xavier RJ et al. Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell 2008; 135: 1311-1323.
47. Lee MJ, Ye AS, Gardino AK, Heijink AM, Sorger PK, Macbeath G et al. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 2012; 149: 780-794.
48. Mondragon L, Orzaez M, Sanclimens G, Moure A, Arminan A, Sepulveda P et al. Modulation of cellular apoptosis with apoptotic protease-activating factor 1 (apaf-1) inhibitors. J Med Chem 2008; 51: 521-529.